A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Participants
The study will evaluate the safety, tolerability, and immunogenicity of a single injection of up to 4 dose levels of IN006 in younger adults and 3 dose levels of IN006 in older adults; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults.
A Phase 1, Randomized, Multicenter, Double-blind, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 69 Years Old
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
A randomized, double-blind, active-controlled, phase I clinical study to evaluate the safety, tolerability, and immunogenicity of a COVID-19 mRNA vaccine (in002.5.1) in comparison with an approved mRNA booster vaccine for COVID-19 in population >= 18 years of age
100 项与 深圳市瑞吉深信生物科技有限公司 相关的临床结果
0 项与 深圳市瑞吉深信生物科技有限公司 相关的专利(医药)
100 项与 深圳市瑞吉深信生物科技有限公司 相关的药物交易
100 项与 深圳市瑞吉深信生物科技有限公司 相关的转化医学